

***The Rate of Fall of Blood Glucose Determines The Necessity of Forebrain-  
Projecting Catecholaminergic Neurons for Male Rat Sympathoadrenal  
Responses***

Anne J. Jokiahho, Casey M. Donovan, and Alan G. Watts

The Center for NeuroMetabolic Interactions, The Integrated and Evolutionary Biology Graduate  
Program, & The Department of Biological Sciences,  
USC Dornsife College of Letters, Arts, and Sciences  
University of Southern California  
Los Angeles, CA 90089-2520

**Running Title:** Hypoglycemia onset rate and brain catecholamines

26 pages  
6 figures  
0 Tables  
3985 words

**Address for Correspondence:**

Alan G. Watts, D.Phil  
Hedco Neuroscience Building, MC 2520  
University of Southern California  
Los Angeles, CA 90089-2520

Phone: (213) 740-1497  
Fax: (213) 741-0561  
E-mail: [watts@usc.edu](mailto:watts@usc.edu)

For Peer Review Only

Diabetes Publish Ahead of Print<sup>®</sup>, published online April 16, 2014

**ABSTRACT**

Different onset rates of insulin-induced hypoglycemia use distinct glucosensors to activate sympathoadrenal counterregulatory responses (CRRs). Glucosensory elements in the portal-mesenteric veins are dispensable with faster rates when brain elements predominate, but are essential for responses to the slower onset hypoglycemia that is common with insulin therapy. Whether a similar rate-associated divergence exists within more expansive brain networks is unknown. Hindbrain catecholamine neurons distribute glycemia-related information throughout the forebrain. We tested in male rats whether catecholaminergic neurons that project to the medial and ventromedial hypothalamus are required for sympathoadrenal CRRs to rapid- and slow-onset hypoglycemia, and whether these neurons are differentially engaged as onset rates change. Using a catecholamine-specific neurotoxin and hyperinsulinemic-hypoglycemic clamps we found that sympathoadrenal CRRs to slow- but not rapid-onset hypoglycemia require hypothalamus-projecting catecholaminergic neurons, the majority of which originate in the ventrolateral medulla. As determined with Fos, these neurons are differentially activated by the two onset rates. We conclude 1), catecholaminergic projections to the hypothalamus provide essential information for activating sympathoadrenal CRRs to slow- but not rapid-onset hypoglycemia; 2), hypoglycemia onset rates have a major impact on the hypothalamic mechanisms that enable sympathoadrenal CRRs; 3), hypoglycemia-related sensory information activates hindbrain catecholaminergic neurons in a rate-dependent manner.

## INTRODUCTION

Insulin therapies still cannot mimic healthy insulin secretion in all circumstances and so iatrogenic hypoglycemia remains the main obstacle to maintaining tight glycemic control in type 1 and later stage type 2 diabetes [1]. Normal counterregulatory responses (CRRs) to hypoglycemia are compromised in type 1 diabetes [2]. Repeated bouts of insulin-induced hypoglycemia (IIH) suppress sympathoadrenal responses to subsequent hypoglycemia, which in turn leads to a maladaptive cycle of repeated bouts of hypoglycemia. Therefore, compromised endocrine counterregulation combined with hypoglycemia unawareness significantly complicates insulin therapies.

Sympathoadrenal and glucocorticoid CRRs to hypoglycemia are mediated by sets of glucosensing elements in the hypothalamus, hindbrain, and portal-mesenteric veins (PMV) [3-6]. PMV-derived glucosensory information reaches the nucleus of the solitary tract (NTS) by way of the spinal cord [7]. Each set of glucosensory elements provides information to a distributed neural network—to enable CRRs [7]. The primacy of brain or peripheral glucosensors for sympathoadrenal CRRs is determined by the rate of fall in glycemia rather than their glycemic thresholds. Brain glucosensing predominates during rapid-onset hypoglycemia, whereas PMV glucosensing is essential with slow-onset hypoglycemia [8]. Establishing how these distributed glucosensing elements integrate information to enable sympathoadrenal CRRs to hypoglycemia is important because evidence suggests that the onset of hypoglycemia with conventional insulin therapy in humans is probably slower than is seen with the intravenous administrations often used experimentally-[9, 10].

Hindbrain glucosensors engage sets of catecholaminergic neurons responsible for feeding and glucocorticoid responses to glycemic challenges [11-14]. Some of these provide a dense

catecholaminergic input to the hypothalamus that originates in certain hindbrain nuclei [15]. Of these, catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus (PVH) are essential for encoding the information that drives ACTH and feeding responses to glycemic perturbations [6,14].

A role for catecholaminergic neurons in regulating sympathoadrenal CRRs is less clear. Beverly and colleagues have shown that hypoglycemia augments norepinephrine release from catecholaminergic terminals into the ventromedial hypothalamus [16]. Furthermore, ventromedial hypothalamic glucose infusions suppress local norepinephrine release and sympathoadrenal CRRs to rapid-onset hypoglycemia [16,17]. These results reveal important interactions between glucosensing mechanisms and catecholaminergic inputs to the ventromedial hypothalamus. However, the necessity of these catecholaminergic neurons has never been tested directly using controlled hyperinsulinemic-hypoglycemic clamps. The fact that sympathoadrenal responses to rapid- and slow-onset hypoglycemia are mediated by different sets of glucosensors [8] raises the possibility that catecholaminergic systems are differentially involved as the rate of fall of blood glucose changes. Here we use immunotoxic lesions to determine if catecholaminergic neurons-projecting to the PVH and ventromedial hypothalamus are required during hypoglycemia and if so, whether they are differentially engaged by rapid- and slow-onset hypoglycemia.

## MATERIALS AND METHODS

**Animals** Individually housed adult male Wistar rats (n=26; BW,  $289 \pm 4.4$ g, at the time of the first surgery) were maintained on a 12h:12h light/dark schedule (lights on 06.00h clock time) in temperature-controlled rooms with continuous access to water and chow (Teklad rodent diet 8604) except where stated. Animals were acclimatized for at least 10 days before surgeries. All procedures were approved by the local Institutional Animal Care And Use Committee.

**Immunotoxic PVH lesions** Catecholaminergic projections to the ventromedial hypothalamus were lesioned with a dopamine- $\beta$ -hydroxylase (DBH) antibody-saporin conjugate (DSAP; Advanced Targeting Systems, San Diego, CA). Isoflurane anesthetized rats were secured in a stereotaxic frame (David Kopf Instruments). Either 42ng/200nl of DSAP (n=14) or equimolar amounts of control mouse IgG-saporin conjugate (MIgG-SAP; n=12) were injected bilaterally into the PVH [14,18].

DSAP mediates the entry of saporin (a cytotoxin) only into neurons expressing DBH on the inner membrane of exocytosed vesicles thereby selectively killing catecholaminergic neurons with terminals proximal to the injection [12,19]. Catecholaminergic neurons with extensive collaterals are lesioned even if DSAP affects only a subset of their terminals. For PVH injections this includes projections to the paraventricular nucleus of the thalamus, supraoptic nucleus, the bed nuclei of the stria terminalis, but not the amygdala [18-20]. The pattern of DBH innervation seen in these extra-hypothalamic areas after DSAP lesions in this study was consistent with these findings. We have previously reported that DSAP lesions have no effect on food intake or body weights for at least 14 days post-surgery [18].

**Catheterizations** At least one week later, all animals were anesthetized (ketamine/xylazine/acepromazine) and catheterized in the right carotid artery for sampling (Clay-

Adams PE-50), and dual left jugular vein catheters (Silastic ID=0.025cm) for insulin/glucose infusions. All catheters were guided subcutaneously and exteriorized dorsally at the neck. A Covance harness (Instech Inc., Plymouth Meeting, PA) was placed around the torso to secure and protect exposed catheters. All animals were allowed 7 days to regain body weight.

***Hyperinsulinemic-hypoglycemic clamps*** The evening before the experiment all food but not water was removed and cannulae connected to a dual channel swivel via a tethering system (Instech Laboratories, Inc., Plymouth Meeting, PA). The next morning jugular catheters were connected to insulin and glucose infusion pumps (Razel Scientific Instruments, Inc., Stamford, CT). Animals were then left undisturbed for 30 minutes. Arterial samples (300 $\mu$ l) were drawn at minute -60 and 0, and four times during the clamps for glucose and catecholamine determinations. Sampled blood was replaced throughout the experiment from donor animals. At minute -60, 25mU•kg•min insulin (Humulin R, human insulin, Lilly, Indianapolis, IN) and variable rate glucose infusions were initiated. Euglycemic clamps were established for 60mins during which blood was sampled every 15 minutes to assure the integrity of the clamp. At minute 0 glucose infusion rates were reduced to achieve deep hypoglycemia ( $\cdot$ 2.5mM) either by minute 20 (rapid-onset; blood glucose sampled every 5 minutes) or minute 70 (slow-onset; blood glucose sampled every 10 minutes). In each case, hypoglycemia was maintained for a further 60mins to minutes 80 or 130, respectively, with blood glucose sampled every 10 minutes. Animals were then rapidly anesthetized with catheter-delivered tribromoethanol. Perfusions, brain removal, post-fixation, cryoprotection, and sectioning were as described previously [21].

***Analytical procedures*** Plasma glucose concentrations were determined using a glucose oxidase/fixd enzyme analyzer (YSI, Yellow Springs, OH). Plasma epinephrine and

norepinephrine concentrations were determined by single-isotope derivative radioenzymatic assays [22] as previously described [23]. All determinations were made in single run assays.

*Immunohistochemistry.* Frozen coronal sections (30 $\mu$ m 1:5 series) were cut through levels 20-29 (for DBH and thionin only) and 58-73 of the Swanson rat brain atlas [24]. Four series were retained for immunocytochemistry; the fifth was thionin stained for cytoarchitectonics. Hindbrain sections were processed immunocytochemically to assess the effect of the clamps and DSAP lesions on three variables in the ventrolateral (VLM) and dorsomedial medulla (NTS; area postrema, AP; dorsal motor nucleus of the vagus, DMX): 1), the number of DBH- and phenylethanolamine N-methyltransferase (PNMT)-expressing neurons; 2), the numbers of Fos-expressing neurons; and 3), the numbers of neurons exhibiting DBH/Fos colocalization. Determining PMNT/Fos colocalization was compromised because both antibodies were raised in rabbits.

Sections were incubated with various combinations of three primary antibodies: a mouse monoclonal anti-DBH antibody (1:10K; MAB308 [14]), a rabbit polyclonal anti-Fos antibody (1:10K, AB-5, Calbiochem, San Diego, CA [25]), a rabbit polyclonal anti-PNMT antibody (1:16K; Dr. Martha Bohn, Northwestern University [26]). The DBH and Fos antibodies were mixed together for colocalization studies. Specific primary antibody binding was detected with donkey anti-mouse IgG secondary antibody conjugated to Alexa 488 (1:500 Invitrogen) for DBH or PNMT, and donkey anti-rabbit IgG conjugated to CY3 (1:500 Jackson ImmunoResearch Labs, West Grove, PA) for Fos.

*Image Acquisition and Analysis.* All images were acquired with a Zeiss AxioImager Z1 microscope (Carl Zeiss MicroImaging, Inc., Thorwood, NY) using either epifluorescence and a Hamamatsu Orca ER camera/Volocity acquisition module (v6.0, PerkinElmer, Waltham, MA),

or a LSM700 with Zeiss Zen software. The numbers of neurons labeled with the various markers were counted manually within anatomically defined regions on unmanipulated epifluorescence images. To assign anatomical boundaries of the A1, A1/C1, and C1 regions of the VLM we referenced sagittal plane coordinates from Geerling et al. [27]. These were matched to Swanson [24] so that the A1 region was located on atlas levels 72 and 73; A1/C1, levels 69-71; and C1, levels 61-68. Cell counts in the NTS and AP were performed with reference to adjacent Nissl sections and level 69-70 of Swanson [24]. All data are reported as the number of labeled cells per section rather than the total number per region [25].

**Data analysis** Results are expressed as means  $\pm$  SEM. Comparisons between groups were made using one-way repeated measures ANOVA and Tukey's post-hoc test for hormone results, or two-way ANOVA and Bonferroni's post hoc test for the neuron counts (Excel, Mac2004, Microsoft; Prism, Mac v4, GraphPad Software). The probability of significance is considered as  $P < 0.05$ .

## RESULTS

### *The Effects of MIgG-SAP or DSAP injections into the PVH on Catecholaminergic Neurons*

*Catecholaminergic Innervation of the Hypothalamus.* MIgG-SAP injected (intact) animals showed robust catecholaminergic (DBH) innervation of the PVH and LHA, particularly lateral to the fornix (Fig. 1A). More caudally, the tuberal nucleus, ARH and those parts of the LHA laterally adjacent to the ventromedial nucleus (VMH) (Fig. 1B) were also heavily innervated. The VMH however, was noticeably devoid of DBH. Virtually all hypothalamic DBH medial to the fornix was eliminated in DSAP-injected-animals (Fig 1 C,D). All lesioned animals exhibited this degree of denervation (n=14); no data were included from any partially lesioned animals.

*DBH and PNMT immunoreactivity in the hindbrain.* Lesioned animals showed a highly significant 60-80% loss of noradrenergic (DBH; Fig. 2A,C) and adrenergic (PNMT; Fig. 2B,D) neurons in the A1, A1/C1, and C1 regions of the VLM compared to intact animals. Lesions had no significant effect on total numbers of DBH neurons in the A2/C2 NTS cell groups and the AP (Fig. 3A,C), there was significant loss of PNMT neurons in the A2/C2 (Fig 3. B,D). PNMT was virtually undetectable in the AP (Fig 3. B,D). Importantly, there was no significant main effect of the lesions on the numbers of DBH and PNMT neurons in any hindbrain region between rapid- and slow-onset IHH.

### *Hyperinsulinemic-Hypoglycemic clamps*

*Arterial plasma glucose concentrations (Figure 4A,B).* Insulin infusions were initiated at -60 mins, and euglycemia established between -60 and 0 mins. At that point plasma arterial glucose concentrations fell from  $5.91 \pm 0.01$  mM (rapid-onset IHH clamps; Fig. 4A) or  $6.10 \pm 0.09$  mM (slow onset clamps; Fig. 4B) to achieve glycemic nadirs of  $2.49 \pm 0.01$  mM by 20 mins (rapid-

onset IIIH) or  $2.47 \pm 0.01$  mM by 75 mins (slow-onset IIIH). There were no significant differences between arterial glucose concentrations at 0 mins in any experimental group. Hypoglycemia was maintained in both rate groups for a further 60 mins. By design, arterial glucose concentrations were carefully matched throughout rapid- and slow-onset clamps.

*Glucose infusion rates during rapid- and slow-onset hypoglycemic-hyperinsulinemic clamps (Figure 4C).* Glucose infusion rates at the onset of the clamps were not significantly different between intact and lesioned animals for both rapid- and slow-onset IIIH. Consistent with their sympathoadrenal CRRs, glucose infusions over the last 60 mins were not significantly different between lesioned and intact animals during rapid-onset IIIH, but infusion rates required to maintain hypoglycemia in slow-onset animals was significantly greater from 75 mins onwards in lesioned animals compared to intact controls.

*Sympathoadrenal Responses To Rapid-Onset Hypoglycemia (Figures 4D,F,G,I).* DSAP lesions had no effect on plasma epinephrine and norepinephrine concentrations at 0 mins. Plasma epinephrine and norepinephrine concentrations both significantly increased in response to IIIH in intact and lesioned animals, and there was no significant difference in plasma epinephrine or norepinephrine concentrations between groups after 60 mins of IIIH.

*Sympathoadrenal Responses To Slow-Onset Hypoglycemia (Figures 4E,F,H,I).* DSAP lesions had no effect on plasma epinephrine and norepinephrine concentrations at 0 mins. But there was a significant suppression of sympathoadrenal CRRs responses after 40 (epinephrine only) and 60 mins (norepinephrine and epinephrine) of IIIH in lesioned animals.

***Fos Activation and Its Colocalization with Catecholaminergic Neurons in The Ventrolateral and Dorsal Medulla.***

*Ventrolateral Medulla.* Fos nuclei were prominent in the A1, A1/C1, and C1 regions of intact and lesioned animals following rapid and slow-onset hypoglycemia (Figs. 5A,6). However, there were no significant interactions between hypoglycemia onset rates and lesions, or any main effects of lesions on the Fos responses to rapid- or slow-onset IHH in any part of the VLM (Fig. 5A).

There were significant interactions between the IHH onset rate and the numbers of DBH/Fos colocalized neurons (Figs. 5B,6) in the A1/C1 ( $F_{1,22} = 11.27$ ,  $P < 0.001$ ) and C1 regions ( $F_{1,22} = 18.17$ ,  $P < 0.001$ ). In all regions numbers were markedly suppressed in animals exposed to slow- compared to rapid-onset IHH. However, this effect was absent in the A1 region ( $F_{1,22} = 0.404$ ) where there were substantially fewer DBH/Fos colocalized neurons than in the more rostral A1/C1 and C1 parts of the VLM.

There were significant main effects of lesions on the numbers of DBH/Fos-colocalized neurons (Figs. 5B, 6A-D) in the A1 ( $F_{1,22} = 5.942$ ,  $P < 0.01$ ), A1/C1 ( $F_{1,22} = 26.15$ ,  $P < 0.001$ ) and C1 ( $F_{1,22} = 29.72$ ,  $P < 0.001$ ) regions in animals with rapid-onset IHH. However, these effects were absent following slow-onset IHH.

*Dorsal Medulla.* Intact animals exposed to rapid- or slow-onset IHH had substantial numbers of Fos neurons in the NTS, but fewer in the AP and DMX (Fig. 5C). The majority of Fos neurons in the NTS were located in its medial part, just medial to the solitary tract (Fig. 6E-H). There were no significant interactions between the IHH onset rate and the numbers of Fos neurons in the AP, NTS, or DMX. However, there were significant main effects of lesions on the numbers of Fos neurons in all three dorsal medullary regions (AP,  $F_{1,21} = 12.69$ ,  $P < 0.01$  rapid only; NTS,  $F_{1,21} = 10.64$ ,  $P < 0.001$  rapid and slow; DMX,  $F_{1,21} = 7.03$ ,  $P < 0.001$  rapid and  $P < 0.01$  slow). Very few

DBH/Fos neurons were seen in the NTS and AP of animals in any treatment group (Fig. 5D, 6D-H), and no comparisons between treatment groups reached statistical significance (Fig. 5D).

## DISCUSSION

We have previously shown that PMV glucosensing mechanisms are essential for generating sympathoadrenal CRRs to slow- but not rapid-onset IHH [8], where brain glucosensors play a more prominent role. Thus, sensory information from slow and rapid onset hypoglycemia is differentially processed, irrespective of the fact that both rates engage sympathoadrenal responses by the time glycemia reaches 2.5mM. Sensory information from the PMV is conveyed to the hindbrain by spinal afferents [23,28] where it drives neuronal activation in the NTS [29-31]. However, where this information goes after leaving the NTS to drive sympathoadrenal responses remain unknown.

Two results now show that as development rates of IHH decrease not only are different glucosensing elements involved, but distinct brain mechanisms are engaged to activate sympathoadrenal CRRs. First, catecholaminergic neurons with projections to the medial hypothalamus are required for sympathoadrenal responses to slow-onset but not rapid-onset IHH. Second, the development rate of IHH markedly alters the activation state of catecholaminergic neurons in the VLM, meaning that how these particular neurons are affected by IHH is determined by its development rate.

Glucosensing mechanisms in the ventromedial hypothalamus are closely associated with endocrine CRRs. They do this using a multi-component complex consisting of, at least, glucosensing neurons [32], contributions from GABAergic and catecholaminergic inputs [16,33], and possibly tanycytes [34,35]. Importantly, our lesions almost certainly eliminate the neurons that release the microdialyzed norepinephrine measured in these studies [16]. Glucosensing neurons have been identified in the PVH [36], but their role in sympathoadrenal

counterregulation is unknown. Furthermore, it is not known whether catecholamine neurons themselves function as classic glucosensors.

Ventromedial hypothalamic glucosensing components interact so that IHH increases norepinephrine release while decreasing GABA release from local terminals [16,37], thereby activating sympathoadrenal CRRs. Conversely, maintaining ventromedial hypothalamic glucose concentrations locally during IHH blocks all of these responses [38]. Altered ventromedial hypothalamic GABA and norepinephrine release therefore requires a fall in ambient glucose that is detected by local glucosensing mechanisms.

A variety of pharmacological manipulations show that glucose-sensitive GABA release into the ventromedial hypothalamus is modulated by adrenergic receptors [39] and by agents that open those ATP-sensitive potassium channels that contribute directly to glucosensing [40]. Thus, Zhu et al. [37] suggest that GABA neurons that are responsive to local glucosensing can restrain endocrine CRRs. This inhibition is removed during IHH. Changes in ambient ventromedial hypothalamic glucose therefore can modulate synaptic norepinephrine and GABA release in a way that influences sympathoadrenal and glucagon CRRs [16,33].

Despite contributions of norepinephrine-dependent mechanisms to glucosensing in the ventromedial hypothalamus, we now show that catecholaminergic inputs to this region are surprisingly not required for sympathoadrenal CRRs to rapid-onset IHH. During rapid-onset IHH glucosensing mechanisms remain fully capable of mediating sympathoadrenal CRRs in the absence of catecholaminergic inputs. One explanation for this effect is that despite the significant rise in ventromedial hypothalamic norepinephrine in these circumstances [16,41], local glucosensing mechanisms by themselves provide adequate reductions in GABA release without a catecholaminergic component. Presumably, increased norepinephrine release in the PVH and

ventromedial hypothalamus contributes to other processes that occur during rapid-onset IIH, notably ACTH release [14,42] and feeding [43].

Sensory information derived from rapid- and slow-onset IIH not only engages different glucosensing elements, but we now show that it must be processed by the brain in a rate-dependent manner. This is clearly evident in the VLM where rapid-onset IIH produces approximately three times more catecholaminergic/Fos neurons than slow-onset IIH. These differences are region-specific because less than 4% of Fos-labeled neurons in the NTS after rapid-onset IIH are catecholaminergic compared to approximately 60% in the more rostral parts of the VLM. However, the very limited Fos activation in our catecholaminergic NTS neurons contrasts with that found after higher doses of 2DG [11], and most likely reflects the different stimulus characteristics of IIH and 2DG. In contrast to DBH/Fos-labeled neurons, we found no differences in the numbers of Fos-labeled neurons in any region examined following either IIH development rate. That the development rate did not affect the number of Fos neurons in the NTS is consistent with our previous results where we also used hyperinsulinemic-clamps to control the development rate of hypoglycemia [30,31].

Despite the fact that forebrain-projecting catecholamine neurons are only required to activate sympathoadrenal CRRs to slow-onset IIH, many more DBH/Fos neurons were seen after rapid-onset IIH. This inverse and seemingly paradoxical relationship between the numbers of Fos-labeled catecholamine neurons in the VLM and their apparent relative importance as development rates of IIH change reveals complex functional interactions between catecholaminergic systems and sympathoadrenal CRRs to IIH. Three points require consideration.

First, in addition to sympathoadrenal CCRs, IIH also generates neuroendocrine, autonomic, and behavioral responses, including ACTH release and feeding [14,44]. During IIH, catecholamine neurons are required to drive ACTH [13,14], feeding (as implied from 2DG-induced feeding) and sympathoadrenal CCRs [12; present study]. Therefore, at least some VLM Fos-labeled catecholamine neurons must subserve events other than sympathoadrenal CCRs. That there is a degree of structural separation between these systems is shown by the fact that feeding and sympathoadrenal CCRs are differentially affected by recurrent IIH [45], and that PVH/ventromedial DSAP lesions that do not affect CCRs following rapid-onset IIH [present study] completely eliminate ACTH responses to bolus iv insulin injections [14] and feeding responses to 2DG [12]. Feeding and ACTH responses are likely driven, at least partly by the large numbers of Fos-labeled catecholaminergic VLM neurons with forebrain projections (based on the number of double-labeled neurons remaining in rapid-onset animals with DSAP lesions). From the numbers of VLM DBH neurons remaining after forebrain DSAP lesions, almost 60% of these project to the PVH/ventromedial hypothalamus. Importantly, these numbers are virtually identical in animals exposed to different development rates of IIH, meaning that differences in CCRs cannot be explained by varying lesion efficacies. Collectively, these results show that sympathoadrenal CCRs, ACTH, and feeding are driven by somewhat separate catecholamine-containing neural networks even though each network receives information from glucosensing elements.

Second, the amount of Fos accumulated by a neuron after a stimulus is not tightly coupled to changes in its action potential frequency. Indeed, increased neuronal firing can occur with no Fos accumulation [46], meaning that the processes driving action potentials do not themselves increase Fos. Instead, *c-fos* transcription requires receptor activation and elevated intracellular

calcium [47]. Slow-onset IHH clearly requires forebrain projecting catecholaminergic neurons. Yet these neurons accumulate significantly less Fos than after rapid-onset IHH. This suggests that the different glucosensing mechanisms engaged by slow- and rapid-onset IHH differentially activate intracellular signaling processes in catecholaminergic neurons, which in turn generates different amounts of Fos. We do not know whether the IHH rate-dependent engagement of those intracellular signals responsible for Fos expression also alters their firing rates in a way that directly impacts sympathoadrenal CRRs.

Third, because our goal was to determine whether the rate of IHH development, rather than IHH itself, affected Fos activation, the experimental design did not require hyperinsulinemic-euglycemic clamps. This means that we cannot completely rule out that at least some neuronal activation derives from hyperinsulinemia rather than IHH. However, hyperinsulinemic-euglycemic clamps result in significantly less NTS Fos expression compared to hypoglycemia [48]. Our findings showing that the two development rates of IHH produced different amounts of DBH/Fos colocalization despite the same insulin dose, argues against hyperinsulinemia being a significant factor. Moreover, the fact that the longer insulin exposures experienced by the slow-onset IHH animals produced the same overall number of Fos labeled neurons as rapid-onset IHH, but less colocalization, shows that colocalization was independent of the duration of insulin exposure.

In terms of potential mechanisms, Beverly and colleagues noted that IHH produces the same magnitude fall in ventromedial hypothalamic glucose-as seen after an overnight fast [49]. Yet we show that sympathoadrenal CRRs only occurs after IHH, not an overnight fast; all our clamped animals were fasted overnight, yet had no sympathoadrenal response before-IHH. Since ambient ventromedial glucose falls much quicker during IHH than fasting, the rate of fall in local glucose

must be an important contributory factor to mechanisms stimulating endocrine CRRs [41]. Fasting reduces ambient ventromedial hypothalamic glucose to that seen during IHH, yet does not increase sympathoadrenal CRRs. Therefore mechanisms additional to those operating during fasting must be required to enable slowly falling ventromedial hypothalamic glucose to activate CRRs during IHH. We now show that catecholamine inputs are well placed to contribute in this manner during slow-onset IHH, perhaps through interactions with local GABAergic terminals. Because the vast majority of VMH neurons are glutamatergic, it seems highly unlikely that the cell bodies of these GABA neurons are located within the VMH [50].

Our results therefore support a mechanism where a catecholaminergic-facilitated fall in GABA release is required during slow-onset but not rapid-onset IHH to activate CRRs. This mechanism may also explain why the slow reduction in ambient glucose seen after fasting [49] is insufficient to drive CRRs because there is no concomitant increase in catecholaminergic activity to facilitate reduced GABA release. Because of the importance of PMV glucosensing mechanisms to slow-onset IHH [8], it is tempting to speculate that at least part of the information encoded by ascending catecholamine neurons derives from glucosensing elements in the PMV.

In summary, we have previously used PMV denervation to show that slow- and rapid-onset IHH use different glucosensing elements to drive sympathoadrenal responses [8]. We now demonstrate that compromising a brain network component—PVH/ventromedial hypothalamus-projecting catecholamine neurons—generates the same outcome as denervating the PMV. The mechanisms used by ventromedial hypothalamic glucosensing and its downstream processes during IHH are therefore determined by the rate of fall of blood glucose. In this way, slow- but not rapid-onset IHH requires information encoded catecholaminergic neurons projecting to the ventromedial hypothalamic glucosensing elements where we suggest they interact with local

GABAergic terminals to maintain sympathoadrenal CRRs. Finally, our Fos results show that glucosensing information is processed in a rate-dependent manner by the brain, and that the outcomes of this processing are then distributed by somewhat different neural networks. The fact that slow-onset IHH may prevail during type-1 diabetes-associated insulin therapy [9,10] shows the importance of fully understanding the functional organization of these glucose-engaged neural networks.

#### **AUTHOR CONTRIBUTIONS**

The study was designed by all three authors, with AGW as the guarantor. The experiments were performed by AJJ, and the results analyzed by AJJ and AGW. The paper was written by AJJ and AGW, with input from CMD.

#### **ACKNOWLEDGEMENTS**

This work was supported by a research grant from the Juvenile Diabetes Research Foundation and NS029728 from NINDS/NIH to AGW. Some findings have been presented in abstract form at the annual meetings of the American Diabetes Association (2010) and the Society for Neuroscience (2012).

The authors have no conflicts of interest to declare.

**REFERENCES**

1. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. *Endocrinol Metab Clin North Am.* 2010 39:641-54
2. Hoeldtke RD, Boden G. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy. *Ann. Intern. Med.* 1994 120:512-517
3. Levin BE, Routh VH, Kang L, Sanders NM, Dunn-Meynell AA. Neuronal glucosensing: what do we know after 50 years? *Diabetes* 2004 53:2521-8
4. Donovan CM. Portal vein glucose sensing. *Diabetes Nutr. Metab.* 2002 15:308–12
5. Hevener AL, Bergman RN, Donovan CM. Novel glucosensor for hypoglycemic detection localized to the portal vein. *Diabetes* 1997 46:1521–1525
6. Ritter S, Li AJ, Wang Q, Dinh TT. Minireview: The value of looking backward: the essential role of the hindbrain in counterregulatory responses to glucose deficit. *Endocrinology.* 2011 152:4019-32
7. Watts, A.G. & Donovan, C.D. Sweet talk in the brain: glucosensing, neural networks, and hypoglycemic counterregulation. *Frontiers in Neuroendocrinology* 2010 31:32-43
8. Saberi M, Bohland M, Donovan CM. The locus for hypoglycemic detection shifts with the rate of fall in glycemia: the role of portal-superior mesenteric vein glucose sensing. *Diabetes.* 2008 57:1380-6.
9. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. *Diabetes Technol Ther.* 2005 7:849-62
10. Bolli GB, Gottesman IS, Cryer PE, Gerich JE. Glucose counterregulation during prolonged hypoglycemia in normal humans. *Am J Physiol.* 1984 247:E206-14
11. Ritter S, Llewellyn-Smith I, Dinh TT. Subgroups of hindbrain catecholamine neurons are selectively activated by 2-deoxy-D-glucose induced metabolic challenge. *Brain Res.* 1998 805:41-54
12. Ritter S, Bugarith K, Dinh TT. Immunotoxic destruction of distinct catecholamine subgroups produces selective impairment of glucoregulatory responses and neuronal activation. *J. Comp. Neurol.* 2001 432:197-216
13. Ritter S, Watts AG, Dinh TT, Sanchez-Watts G, Pedrow C. Immunotoxin lesion of hypothalamically projecting norepinephrine and epinephrine neurons differentially affects circadian and stressor-stimulated corticosterone secretion. *Endocrinology* 2003 144:1357–1367
14. Khan, A.M., Kaminski, K.L., Sanchez-Watts, G., Ponzio T.A., Kuzmiski, J.B., Bains, J.S., & Watts, A.G. MAP kinases couple hindbrain-derived catecholamine signals to hypothalamic adrenocortical control mechanisms during glycemia-related challenges. *J. Neuroscience* 2011 31:18479 –18491.
15. Swanson LW, Hartman BK. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. *J. Comp. Neurol.* 1975 163:467–505.

16. Beverly JL, de Vries MG, Bouman SD, Arseneau LM. Noradrenergic and GABAergic systems in the medial hypothalamus are activated during hypoglycemia. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2001 280:R563-9
17. de Vries MG, Lawson MA, Beverly JL. Hypoglycemia-induced noradrenergic activation in the VMH is a result of decreased ambient glucose. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2005 289:R977-81
18. Kaminski, K.L., Watts A.G. Intact catecholamine inputs to the forebrain are required for appropriate regulation of corticotrophin-releasing hormone and vasopressin gene expression by corticosterone in the rat paraventricular nucleus. *J. Neuroendocrinol.* 2012 24:1517-26
19. Ritter S, Dinh TT, Bugarith K, Salter DM. Chemical Dissection of Brain Glucoregulatory Circuitry. In *Molecular Neurosurgery With Targeted Toxins*. RG Wiley, DA Lappi, Eds. Totowa, New Jersey, Humana Press Inc., 2005, p. 181-218
20. Banihashemi L, Rinaman L (2006) Noradrenergic inputs to the bed nucleus of the stria terminalis and paraventricular nucleus of the hypothalamus underlie hypothalamic-pituitary-adrenal axis but not hypophagic or conditioned avoidance responses to systemic yohimbine. *J Neurosci* 26:11442–11453.
21. Khan, A.M., Ponzio, T.A., Sanchez-Watts, G., Stanley, B.G., Hatton, G.I. & Watts, A.G. Catecholaminergic control of MAP kinase signaling in paraventricular neuroendocrine neurons in vivo and in vitro: A proposed role during glycemic challenges. *J. Neuroscience* 2007 27:7344-7360.
22. Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. *Life Sci* 1977 21:625-636.
23. Fujita S, Bohland M, Sanchez-Watts G, Watts AG, Donovan CM. Hypoglycemic detection at the portal vein is mediated by capsaicin-sensitive primary sensory neurons. *Am. J. Physiol. Endocrinol. Metab* 2007 293:E96-E101
24. Swanson LW. *Brain Maps: Structure of the Rat Brain*, 3rd edn. San Diego, CA: Academic Press, 2004.
25. Watts AG, Sanchez-Watts G. Rapid and preferential activation of Fos protein in hypocretin/orexin neurons following the reversal of dehydration-anorexia. *J Comp Neurol.* 2007 502:768-82
26. Bohn MC, Dreyfus CF, Friedman WJ, Markey KA. Glucocorticoid effects on phenylethanolamine N-methyltransferase (PNMT) in explants of embryonic rat medulla oblongata. *Dev. Brain Res.* 1987 37:257-66.
27. Geerling JC, Shin J-W, Chimenti PC, Loewy AD. Paraventricular hypothalamic nucleus: Axonal projections to the brainstem. *J. Comp. Neurol.* 2010 518:1460-99
28. Fujita S, Donovan CM. Celiac-superior mesenteric ganglionectomy, but not vagotomy, suppresses the sympathoadrenal response to insulin-induced hypoglycemia. *Diabetes* 2005 54:3258–3264
29. Adachi A, Shimizu N, Oomura Y, Kobashi M. Convergence of hepatoportal glucose-sensitive afferent signals to glucose-sensitive units within the nucleus of the solitary tract. *Neurosci Lett.* 1984 46:215-8

30. Bohland, M., Watts, A.G. & Donovan, C. Celiac-superior mesenteric ganglionectomy attenuates hypoglycemic activation of hindbrain neurons (Abstract). *Am. Diabetes Assoc* 2006; Vol 55 (Suppl.1):A16: 68-OR
31. Bohland, M., Watts, A.G. & Donovan, C. Activation of hindbrain and PVH Neurons is independent of peripheral glucose sensory input in response to rapidly developing hypoglycemia (Abstract). *Am. Diabetes Assoc* 2007; Vol 56 (Suppl 1):A100: 382-OR
32. Kang L, Routh VH, Kuzhikandathil EV, Gaspers LD, Levin BE. Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons. *Diabetes*. 2004 53:549-59.
33. Chan O, Paranjape S, Czyzyk D, Horblitt A, Zhu W, Ding Y, Fan X, Seashore M, Sherwin R. Increased GABAergic output in the ventromedial hypothalamus contributes to impaired hypoglycemic counterregulation in diabetic rats. *Diabetes*. 2011 60:1582-9.
34. Sanders NM, Dunn-Meynell AA, Levin BE. Third ventricular alloxan reversibly impairs glucose counterregulatory responses. *Diabetes* 2004 53:1230-6
35. Levin BE, Magnan C, Dunn-Meynell A, Le Foll C. Metabolic sensing and the brain: who, what, where, and how? *Endocrinology*. 2011 152:2552-7.
36. Melnick IV, Price CJ, Colmers WF. Glucosensing in parvocellular neurons of the rat hypothalamic paraventricular nucleus. *Eur J Neurosci*. 2011 34:272-82.
37. Zhu W, Czyzyk D, Paranjape SA, Zhou L, Horblitt A, Szabó G, Seashore MR, Sherwin RS, Chan O. Glucose prevents the fall in ventromedial hypothalamic GABA that is required for full activation of glucose counterregulatory responses during hypoglycemia. *Am J Physiol Endocrinol Metab*. 2010 298:E971-7.
38. Borg MA, Sherwin RS, Borg WP, Tamborlane WV, Shulman GI. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. *J Clin Invest*. 1997 99:361-5
39. Szepietowska B, Zhu W, Chan O, Horblitt A, Dziura J, Sherwin RS. Modulation of  $\beta$ -adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia. *Diabetes*. 2011 60:3154-8.
40. Chan O, Lawson M, Zhu W, Beverly JL, Sherwin RS. ATP-sensitive K(+) channels regulate the release of GABA in the ventromedial hypothalamus during hypoglycemia. *Diabetes*. 2007 56:1120-6
41. Barnes MB, Lawson MA, Beverly JL. Rate of fall in blood glucose and recurrent hypoglycemia affect glucose dynamics and noradrenergic activation in the ventromedial hypothalamus. *Am J Physiol Regul Integr Comp Physiol*. 2011 301:R1815
42. Pacák K, Palkovits M. Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. *Endocr Rev*. 2001 22:502-48
43. Leibowitz SF, Sladek C, Spencer L, Tempel D. Neuropeptide Y, epinephrine and norepinephrine in the paraventricular nucleus: stimulation of feeding and the release of corticosterone, vasopressin and glucose. *Brain Res Bull*. 1988 21:905-12

44. Grossman SP. The role of glucose, insulin and glucagon in the regulation of food intake and body weight. *Neurosci Biobehav Rev.* 1986 10:295-315.
45. Sanders NM, Figlewicz DP, Taborsky GJ Jr, Wilkinson CW, Daumen W, Levin BE. Feeding and neuroendocrine responses after recurrent insulin-induced hypoglycemia. *Physiol Behav.* 2006 87:700-6.
46. Luckman SM, Dyball RE, Leng G. Induction of c-fos expression in hypothalamic magnocellular neurons requires synaptic activation and not simply increased spike activity. *J Neurosci.* 1994 14:4825-30.
47. Watts, A.G., Khan, A.M. Sanchez-Watts, G., Salter, D., & Neuner, C.M. Activation in neural networks controlling ingestive behaviors: what does it mean and how do we map and measure it? *Physiol Behav.* 2006 89:501-10.
48. Ao Y, Wu S, Go VL, Toy N, Yang H. Maintaining euglycemia prevents insulin-induced Fos expression in brain autonomic regulatory circuits. *Pancreas.* 2005 31:142-7.
49. de Vries MG, Arseneau LM, Lawson ME, Beverly JL. Extracellular glucose in rat ventromedial hypothalamus during acute and recurrent hypoglycemia. *Diabetes.* 2003 52:2767-73.
50. Ziegler DR, Cullinan WE, Herman JP. Distribution of vesicular glutamate transporter mRNA in rat hypothalamus. *J. Comp. Neurol.* 2002 448:217–229.

## FIGURES LEGENDS

### Figure 1

Fluorescence photomicrographs of coronal sections through the hypothalamus of rats showing catecholaminergic innervation revealed with dopamine- $\beta$ -hydroxylase immunocytochemistry. Animals were injected in the paraventricular nucleus of the hypothalamus with either a mouse immunoglobulin-saporin (MIgG-SAP; A,B) or an anti-dopamine- $\beta$ -hydroxylase conjugate (DSAP; C,D). Sections correspond to levels 26 (A,C) and 28 (B,D) of Swanson [2004]. Note the profound loss of catecholaminergic innervation in the mediobasal hypothalamus of the animal injected with DSAP (C,D) compared to that injected with MIgG-SAP (A,B). Abbreviations: 3V, third ventricle; AHN, anterior hypothalamic nucleus; ARH, arcuate nucleus; fx, fornix; LHA, lateral hypothalamic area; ot, optic tract; PVH, paraventricular nucleus of the hypothalamus; RCH, retrochiasmatic area; TU, tuberal nucleus; VMH, ventromedial nucleus of the hypothalamus.

### Figure 2

Animals injected in the paraventricular nucleus of the hypothalamus with an anti-dopamine- $\beta$ -hydroxylase conjugate (DSAP) show a significant loss of dopamine- $\beta$ -hydroxylase (DBH; A,C) and phenylethanolamine N-methyltransferase (PNMT; B,D) immunoreactive neurons in the A1, A1/C1, C1 regions of the ventrolateral medulla (VLM) compared to animals injected with a mouse immunoglobulin-saporin conjugate (MIgG-SAP). Animals were exposed to either rapid- (open bars) or slow-onset (solid bars) hyperinsulinemic-hypoglycemic clamp. Results in A) and B) are expressed as mean (+ standard error of the mean) number of labeled cells per section. C) and D) show DBH and PNMT in the A1 (DBH only) and C1 regions of the VLM.

### Figure 3

Animals injected in the paraventricular nucleus of the hypothalamus with an anti-dopamine- $\beta$ -hydroxylase conjugate (DSAP) show a significant loss of dopamine- $\beta$ -hydroxylase (DBH; A,C) and phenylethanolamine N-methyltransferase (PNMT; B,D) immunoreactive neurons in the area postrema (AP) and nucleus of the solitary tract (NTS) compared to animals injected with a mouse immunoglobulin-saporin conjugate (MIgG-SAP). Animals were exposed to either rapid- (open bars) or slow-onset (solid bars) hyperinsulinemic-hypoglycemic clamp. Results in A) and B) are expressed as mean (+ standard error of the mean) number of labeled cells per section.

Abbreviations in C) and D): AP, area postrema; c, central canal, spinal cord/medulla; co, commissural part of the NTS; DMX, dorsal motor nucleus of the vagus; ge, gelatinous part of the NTS; m, medial part of the NTS; ts, solitary tract.

#### Figure 4

Sympathoadrenal hormone responses to rapid- and slow-onset insulin-induced hypoglycemia. Panels A) and B), the mean ( $\pm$  standard error of the mean) arterial glucose concentrations in animals injected in the paraventricular nucleus of the hypothalamus with either a mouse immunoglobulin-saporin (MIgG-SAP; solid symbols) or an anti-dopamine- $\beta$ -hydroxylase conjugate (DSAP; open symbols) and exposed to a rapid- or slow-onset hyperinsulinemic-hypoglycemic clamp. C) Corresponding glucose infusion rates. Plasma epinephrine (D - F) and norepinephrine (G - I) responses to the hyperinsulinemic-hypoglycemic clamps. F) and I) show the plasma epinephrine and nor-epinephrine concentrations at 0 mins (open bars) and after 60 mins (solid bars) of hypoglycemia. In all panels except F) & I) the light gray area denotes the onset duration of hypoglycemia, the dark gray area denotes the duration of hypoglycemia (2.5mM). \*,  $P < 0.02$ ; \*\*,  $P < 0.001$  \*\*\*,  $P < 0.0002$ ; \*\*\*\*,  $P < 0.0001$ .

#### Figure 5

Mean (+ standard error of the mean) numbers of Fos (A,C) and Fos/DBH (B,D) colocalized neurons per section in the A1, A1/C1, and C1 regions of the ventrolateral medulla (A,B) and dorsal medulla (C,D). Animals were injected in the paraventricular nucleus of the hypothalamus with either a mouse immunoglobulin-saporin (MIgG-SAP) or an anti-dopamine- $\beta$ -hydroxylase conjugate (DSAP) and exposed to a rapid- (open bars) or slow-onset (solid bars) hyperinsulinemic-hypoglycemic clamp. Abbreviations: AP, area postrema; DMX, dorsal motor nucleus of the vagus; NTS, nucleus of the solitary tract.

#### Figure 6

Confocal photomicrographs showing dopamine- $\beta$ -hydroxylase (DBH; green fluorophore) and Fos (red fluorophore) immunoreactive elements in the C1 region of the ventrolateral medulla (A – D) and dorsal medulla (E - H) of animals injected in the paraventricular nucleus of the hypothalamus with either a mouse immunoglobulin-saporin conjugate (MIgG-SAP) or an anti-dopamine- $\beta$ -hydroxylase conjugate (DSAP). Animals were exposed to either rapid- (Rapid) or

slow-onset (Slow) hyperinsulinemic-hypoglycemic clamp. The white rectangle in each main panel is the region shown at higher magnification in the accompanying panel (A' – H'). The arrowheads in A) – D) indicate representative DBH/Fos double-labeled neurons (solid) and DBH or Fos singly labeled neurons (open). The brightness and contrast of each panel was adjusted uniformly to achieve balance across the entire panel using combinations of the brightness/contrast and curves (gamma correction) tools in Adobe Photoshop CS3 (Adobe Inc.) Abbreviations in E) – H) are the same as in Figure 3. Please note that brightness/contrast manipulations were only used for the photomicrographs and were not performed on images from which the data used to derive the quantitative results shown in Figs. 2, 3, & 5 were obtained. None of the manipulations changed the nature of the results.




Figure 1. DSAP Lesion photomicrograph  
150x146mm (300 x 300 DPI)




Figure 2. DBH-PNMT in A1-C1  
194x194mm (600 x 600 DPI)




Figure 3. DBH-PNMT in A2  
205x308mm (600 x 600 DPI)




Figure 4. Blood glucose and plasma epinephrine/norepinephrine results  
 205x211mm (300 x 300 DPI)




Figure 5. DBH-Fos colocalization quantitation  
161x133mm (300 x 300 DPI)




Figure 6. DBH-Fos colocalization photomicrographs  
255x469mm (300 x 300 DPI)